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Abstract
Nonalcoholic fatty liver disease (NAFLD), defined as 
abnormal accumulation (> 5%) of hepatic triglyceride 
without excess alcohol intake, is the most common 
form of chronic liver disease in adults and children in 
the United States. NAFLD encompasses a spectrum of 
histologic findings including uncomplicated steatosis, 
steatosis with inflammation and steatohepatitis [nonal-
coholic steatohepatitis (NASH)]; the latter can advance 
to cirrhosis and hepatocellular carcinoma. NASH is 
currently accepted as the hepatic manifestation of the 
set of cardiovascular risk factors collectively known as 
metabolic syndrome. In 1999 a system for histologic 
grading and staging for NASH was proposed; this was 
revised by the NASH Clinical Research Network in 2005 
for the entire spectrum of lesions in NAFLD, including 
the lesions and patterns of pediatric NAFLD, and for 
application in clinical research trials. Diagnosis remains 
distinct from grade and stage. A recent European 
proposal separates steatosis from activity to derive a 
numeric diagnosis of NASH. Even though there have 
been promising advancements in non-invasive testing, 
these tests are not yet detailed enough to replace the 
full range of findings provided by liver biopsy evalua-
tion. Limitations of biopsy are acknowledged, but liver 
biopsy remains the “gold standard” for diagnosis and 
determination of amounts of necroinflammatory activ-
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ity, and location of fibrosis, as well as remodeling of the 
parenchyma in NASH. This review focuses on the spe-
cific histologic lesions of NAFLD and NASH, grading and 
staging, differential diagnoses to be considered, and 
the continuing role of the liver biopsy in this important 
liver disease.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Nonalcoholic fatty liver disease (NAFLD) is the 
most common form of chronic liver disease; no clini-
cal or serologic tests have yet replaced liver biopsy for 
definitive diagnosis. The histologic spectrum includes 
steatosis, steatohepatitis, and cirrhosis with or without 
active steatohepatitis. Hepatocellular carcinoma may 
occur in cirrhosis, or prior to cirrhosis. Liver biopsy pro-
vides vital data for patient care, clinical trials, and for 
ongoing research into nuances of the disease process. 
The histologic spectrum of NAFLD, features with co-
existent diseases, differential diagnoses, grading and 
staging methods and the role of liver biopsy, as well as 
a brief description of non-invasive alternatives, are dis-
cussed.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), defined as 
abnormal accumulation of  triglycerides in the liver (i.e., > 
5%) in the absence of  significant alcohol intake, is recog-
nized as the most common cause of  chronic liver disease, 
and is estimated to affect 30% of  adults and 10% of  
children in United States[1]. The prevalence of  NAFLD 
parallels that of  metabolic syndrome, insulin resistance, 
type 2 diabetes and central obesity[2]. It is currently rec-
ognized that mortality in the majority of  individuals with 
NAFLD is more likely from cardiovascular diseases than 
from liver disease[3], thus, even though recent studies 
have documented similar epidemiologic and histologic 
features of  NAFLD and nonalcoholic steatohepatitis 
(NASH) in the geriatric population[4,5], this age group will 
not be further discussed in this review. The prevalence 
is highest in the ethnic Hispanic population, followed by 
non-Hispanic whites, Asians and African Americans[6,7]. 
The prevalence increases significantly up to 80%-90% in 
obese adults, 60% in patients with hyperlipidemia, and 
30%-50% in diabetics[2]. Only a minority of  subjects with 
steatohepatitis actually progress to fibrosis or cirrhosis[8]. 
Currently, however, NAFLD is the third most common 
cause of  liver transplantation in United States[9], and is 
projected to be the leading cause of  liver transplantation 
in the United States by 2020[1]. In addition, approximately 
4%-22% of  hepatocellular carcinomas in the Western 
world are attributed to NAFLD[10]. Hepatocellular car-
cinoma may develop in either cirrhosis or non-cirrhotic 
NAFLD, as recently reviewed[10,11].
NAFLD is a spectrum of  histologic lesions of  ste-
atosis at one end, and steatohepatitis and cirrhosis at the 
other[12]. However, whether in a given patient there is ac-
tual “progression” from steatosis to steatohepatitis with-
out concurrent clinical complications such as weight gain, 
or new onset diabetes, has not been adequately studied. 
What is accepted is that steatosis itself  is considered 
“non-progressive” whereas steatohepatitis is the constel-
lation of  lesions with potential to progress; this was first 
shown in a seminal series of  Matteoni et al[13]. Thus, the 
ability of  the liver biopsy is to separate individuals with 
steatohepatitis from those with “only” steatosis (which 
includes steatosis with inflammation); this is an impor-
tant goal that any diagnostic test should meet. NASH is 
defined histopathologically by the presence of  a constel-
lation of  features: steatosis, lobular and portal inflam-
mation and liver cell injury in the form of  hepatocyte 
ballooning. Initially, in adults, the ballooning and fibrosis 
are in a zone 3 distribution; once abnormal matrix is 
deposited (i.e., fibrosis), and architectural remodeling oc-
curs, the zonality of  injury is less apparent.
Many advances have occurred since the initial recog-
nition that fatty liver disease could occur in overweight 
and/or diabetic subjects who weren’t over-exposed 
to alcohol by several researchers including Thaler[14], 
Klatskin et al[15], Schaffner et al[16] and Ludwig et al[17] in the 
late 1970’s and early 1980’s. These include histopathologic 
work in humans with careful clinical correlations discern-
ing the prevalence of  NAFLD and NASH[18], the roles 
of  progenitor cells and the ductular reaction in fibrogen-
esis[18-21], and the role of  innate and adaptive immune-
mediated mechanisms in steatohepatitis[22], progression 
of  steatohepatitis to cirrhosis and hepatocellular carci-
noma[10,23,24] and genetic and genomic underpinnings of  
disease susceptibility and progression[25,26].
LIVER BIOPSY: ROLE, INDICATIONS, 
AND DRAWBACKS
The general indications for performing a liver biopsy in 
patients with NAFLD are to confirm or exclude the di-
agnosis, diagnose other liver diseases, and to determine 
amounts of  damage to the liver for treatment and prog-
nosis. The last includes necroinflammatory activity, which 
is potentially reversible, and collagen deposition with 
varying degrees of  remodeling, which is potentially less 
reversible. More specific indications have been recently 
stated. According to the 2012 guidelines from American 
Association for the Study of  Liver Disease (AASLD), 
liver biopsy should be reserved for subjects who will 
“benefit”, for subjects with potentially competing diagno-
ses, and for children with either an unclear diagnosis or in 
whom consideration is being given for medication[27]. The 
European Association for the Study of  Liver Disease po-
sition statement on liver biopsy differed slightly and rec-
ommended liver biopsy in all bariatric surgery subjects, 
and as an endpoint in all clinical trials[28]. Liver biopsy 
remains the standard against which noninvasive (serologic 
and imaging) methods are judged in order to assess these 
features. By histologic evaluation, one is able to distin-
guish between NASH, a lesion with progressive potential, 
and no NASH, lesions without potential to progress[28-33].
Performing a liver biopsy on every patient with sus-
pected NAFLD remains a controversial subject in daily 
practice, and clearly is not a practical consideration as a 
“screening” tool. There are studies, however, that support 
the value of  liver biopsy. A frequently cited albeit older 
study by Skelly et al[34] showed that of  354 biopsied patients 
with otherwise unexplained abnormal liver tests 66% had 
fatty liver, 50% of  those had steatohepatitis, approximately 
19% of  the remaining biopsies had other treatable causes 
diagnosed by the pathology evaluation including autoim-
mune hepatitis (AIH), primary biliary cirrhosis (PBC), he-
mochromatosis and alcoholic liver disease (ALD).
A more recent study used a modeling system to show 
that obtaining a liver biopsy could provide survival ben-
efit to patients with NAFLD. Gaidos et al[35] evaluated 
the long-term benefit of  biopsy vs no biopsy. The study 
showed that performing an early liver biopsy resulted in a 
higher percentage of  having mild liver disease ultimately 
in NAFLD patients. Early diagnosis and treatment re-
sulted in decrease in progression to severe disease or 
transplant and a predicted survival advantage in NAFLD 
patients. In addition, the risk of  death related to liver bi-
opsy did not offset the survival advantage. Others have 
demonstrated the benefits of  liver biopsy in NAFLD 
by demonstrating the presence of  NAFLD or NASH in 
“atypical settings” such as concurrent disease processes 
such as Hepatitis C[36-38], AIH, PBC, hereditary hemo-
chromatosis (HH)[36], as well as drugs and occupational 
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exposures[39-41]. Liver biopsy studies proved the validity 
of  the concept of  the presence of  all ranges of  necro-
inflammatory activity and fibrosis, including cirrhosis, in 
the presence of  normal alanine aminotransferase values 
in adults[42-44], and children[45]. The current state of  inves-
tigation for pathologists is to evaluate which subjects will 
develop fibrosis and why, and which findings on early 
biopsies, if  any, may be predictive of  future outcomes.
Liver biopsy studies have given insight into natural 
history of  NASH, albeit in a selected group of  primar-
ily adult subjects. The prevalence of  NASH, 12.2% of  
over 300 multi-ethnic adult subjects, was established in 
a Texas city by liver biopsy in an unbiased community 
who were willing to undergo ultrasound and subsequent 
liver biopsy. Nearly 30% had evidence of  NAFLD by 
ultrasound[18]. This was the first study of  its kind in 
adults, as all prior studies had been done either in living 
donors, who did not have evidence of  steatohepatitis, or 
in autopsies. Liver pathology evaluation was the first to 
establish the remarkable incidence of  fatty liver of  up to 
13% in an autopsy study of  children who died from ac-
cidental deaths[46]. Liver biopsy further characterized the 
association of  cardiovascular disease and biopsy proven 
NAFLD in 150 overweight children compared with 150 
overweight children without NAFLD[47].
At the current time, it remains common practice to 
attribute cases of  cryptogenic cirrhosis to burned out 
“NASH”. This is not altogether appropriate unless there 
is prior biopsy proof  of  NASH because clinically it is 
known that other forms of  liver injury can “burn out”, in 
particular alcoholic liver disease and autoimmune liver dis-
ease. It was liver biopsy studies that indicated that NASH 
may be one of  the underlying causes of  cryptogenic cir-
rhosis, which, by definition, has no serologic markers for 
determination of  cause of  liver disease. This was shown 
in a small case series[48] then larger case studies compar-
ing NAFLD-related cirrhosis to cirrhosis related to other 
forms of  serologically diagnosed chronic liver disease[49], 
and finally in kindred studies[50]. Liver biopsy in cirrhosis 
of  otherwise unknown etiology can show evidence of  
ongoing steatohepatitis, or burned out disease without 
any activity or steatosis in subjects with clinical features 
of  metabolic syndrome. Additionally, not only will NASH 
progress to advanced fibrosis and cirrhosis in a subset of  
individuals if  the underlying metabolic conditions are un-
changed, but several studies have verified that NASH may 
also regress spontaneously, as reviewed[51]. This phenom-
enon has largely been observed in either placebo arms or 
in the non-responders of  treatment trials[52-54].
In 2009, an AASLD sponsored workshop raised im-
portant questions for advancement in the field of  NAFLD, 
providing guidance for investigators for clinical design 
and end points including pathologic and laboratory 
data[55]. As evidenced by published recommendations, liv-
er biopsy is an important tool in clinical trials. Outcomes 
remain based on histologic features which provide infor-
mation regarding the effects of  intervention on extent 
and severity of  hepatocellular injury, inflammation, and 
architectural alterations as well as the ultimate diagnosis. 
To date, histologic evaluation remains the “hard end-
point” that can be measured with the most reliability[12]. 
The most commonly used tool for histologic evaluation 
is the nonalcoholic fatty liver disease activity score (NAS) 
(Details will be discussed in later in the text). The NAS 
was not intended to replace the diagnosis but to provide 
a sensitive tool to assess the changes that might occur 
with treatment[56]. However, unintended use of  this score 
has been noted by the investigators[56]. A study by NASH 
clinical research network (CRN), including 976 adult liver 
biopsies, challenged this concept and demonstrated that 
while the NAS correlated with the diagnosis, it was in 
the lower and higher ends of  the spectrum. Therefore, if  
NAS were to reflect the diagnosis, a significant portion 
of  these patients would be misclassified[56]. Most impor-
tantly diagnosis of  NASH was strongly associated with 
the presence of  diabetes, quantitative insulin sensitivity 
check index (QUICKi) and homeostasis model assess-
ment-estimated insulin resistance (HOMA-IR)[56] while 
the diagnosis and the NAS both correlated with amino-
transferases. This data further supported the concept that 
scoring lesions and diagnosing patterns of  injury are dif-
ferent processes for a pathologist[29,56].
LIVER BIOPSY LIMITATIONS
Liver biopsy, as useful as it is, however, does have limita-
tions. The major limitation of  liver biopsy is the invasive 
nature of  the procedure. Though considered “minimal”, 
liver biopsy is an invasive procedure and can have com-
plications even in the ideal clinical conditions, including 
pain, minor and major bleeding (0.3%). Organ perfora-
tion is uncommon, but more likely in blind biopsy. Death 
albeit rare, has been reported at 0.01%[57]. Currently, the 
majority of  liver biopsies are performed under ultrasound 
guidance. As with liver biopsy interpretation, operator 
experience is an important factor in success[58].
As in other chronic liver diseases, biopsy size is an 
important, but often unrecognized consideration in diag-
nostic accuracy[12,59,60]. A biopsy, at least 1.6 cm in length 
with 1.2-1.8 mm diameter, containing approximately 10 
portal tracts is considered adequate[61,62]. Even then an ad-
equate liver biopsy represents approximately 1:50.000 of  
the entire organ[63].
Some limitations of  liver biopsy are due to variability 
of  the disease process itself, as with all other forms of  
chronic liver disease. NAFLD, while a diffuse process of  
the liver, can have differences particularly in fibrosis due 
to the location of  the samples under evaluation. The sub-
capsular liver tissue is generally more fibrotic, and the left 
lobe has larger portal areas near the capsule than the right. 
Thus, it is important, particularly for studies, that both pre 
and post study biopsies are done in a similar fashion and 
from the same region of  the liver[12]. Authors have not 
always agreed on the amounts of  histologic sampling vari-
ability in NAFLD. Larson et al[62] found minimal variability 
in steatosis, NAS ≥ 5 and fibrosis between two samples 
in bariatric subjects. The study also emphasized the need 
for not only appropriate length, but also width of  liver bi-
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entertained. Steatosis initially is found predominantly in 
hepatocytes around the terminal hepatic venule (zone 
3); when abundant, steatosis can be panacinar, and when 
resolving, may be irregular, or azonal. The type of  tri-
glyceride accumulation that is observed in NAFLD is 
predominantly macrovesicular and is typically character-
ized by a single or a few lipid droplets within the affected 
hepatocytes, displacing the nucleus peripherally within 
the cell (Figure 1A). When the droplets are smaller, i.e., 
“small droplet” steatosis, they are well-defined and easily 
delineated from one another. Small droplets often form 
droplets around the larger droplets and may coalesce 
to form the macrodroplet. Albeit small, these types of  
droplets should not be confused for true “microvesicular” 
steatosis, as the pathophysiology and thus implications 
for liver function differ (Figure 1B). Microvesicular ste-
atosis may occur in a patchy distribution in up to 10 % of  
NASH cases[68,69], and has been shown in a large study to 
be associated with ballooned hepatocytes, and advanced 
fibrosis[69].
There are a constellation of  histopathologic lesions 
required for the diagnosis of  steatohepatitis. These in-
clude steatosis, inflammation (lobular and portal) and 
hepatocyte injury, commonly in the form of  ballooning. 
Ballooned hepatocytes appear as enlarged hepatocytes 
with a flocculent, cleared appearance of  the cytoplasm 
with irregular cytoplasmic borders[30,70] (Figure 1C). Often 
the nucleus is hyperchromatic. Hepatocyte ballooning has 
been shown to correlate with oxidative damage[71] and mi-
crotubule disruption[30,70], and loss of  normal structure of  
the cytoskeleton[71,72]. In adult NASH, ballooned hepato-
cytes are most commonly seen in zone 3 and if  fibrosis is 
present, they are intermixed with perisinusoidal collagen 
fibers. Keratins 8/18, present throughout the cytoplasm 
of  all normal hepatocytes[72], are damaged in ballooned 
hepatocytes; this is manifest with loss of  cytoplasmic 
immunoexpression (Figure 1D), movement to submem-
branous location, and highlighting of  Mallory-Denk 
bodies (MDB)[73]. MDB are ubiquitinated keratins and cy-
toskeletal structures within the proteosome (Figure 1E). 
p62 and ubiquitin are immunomarkers that label MDB[74]. 
By trichrome stain, MDB can be blue or green (Figure 
1F). In NASH, MDBs are often less well-formed than in 
alcoholic hepatitis or alcoholic steatohepatitis[75]. Finally, 
ballooning has been associated with several relevant clini-
cal markers such as measures of  insulin resistance[76], 
increased serum cholesterol[76,77] and serum markers of  
necroinflammation[78]. Similar correlations have also been 
noted in the pediatric population[79].
Lobular inflammation, typically more prominent than 
portal inflammation in uncomplicated adult NAFLD, 
is mostly mononuclear, but also includes Kupffer cell 
clusters, microgranulomas with or without lipid droplets, 
and larger lipogranulomas (Figure 1G). Lefkowitch noted 
prominent enlargement and aggregation of  Kupffer cells 
around terminal hepatic venules in NASH, in contrast to 
the even distribution in normal livers and uncomplicated 
steatosis[80]. Kupffer cells, the largest resident macrophage 
opsy needle. Another study in morbidly obese individuals 
undergoing bariatric surgery found moderate histologic 
variability between lobes[64]. In two additional studies, one 
in bariatrics and one in non-morbidly obese subjects, two 
separate biopsies from the same location in the same lobe 
were graded and staged independently and showed one or 
more points in discordance in fibrosis stage[59,60]. In addi-
tion hepatocyte ballooning, one of  the diagnostic require-
ments of  NASH, was not present in 24% of  patients in 
one study in one set of  the biopsies[60]. The implications 
for clinical studies for evaluating pre and post treatment 
biopsies are apparent.
The experience of  the pathologist also plays a sig-
nificant role in making the diagnosis of  NAFLD; this is 
similar to other liver diseases[58]. The interobserver agree-
ments on steatosis, ballooning and fibrosis were good 
amongst pathologists in the study of  Kleiner et al[65] that 
included 32 adult biopsies and 9 pathologists but not so 
strong for location of  steatosis and for inflammation[66]. 
Similar observations were reported in a study of  21 liver 
biopsies read by eight experienced Japanese hepato-
pathologists with good agreement on fibrosis and extent 
of  steatosis. Younossi et al[67], showed good concordance 
for extent of  steatosis and degree of  fibrosis along with 
ballooned hepatocytes in 53 liver biopsies interpreted by 
4 experienced liver pathologists.
The high prevalence of  NAFLD in the popula-
tion and the limitations, risks and cost of  liver biopsy 
have led investigators to seek for non-invasive methods 
to diagnose, and stage NALFD. The ideal test would 
be cheap, reproducible, and would be able to diagnose 
the full spectrum of  NAFLD, predict fibrosis, and also 
reflect changes that occur with treatment[31,32]. Several 
different methodologies including imaging modalities, 
serum markers and combined tests are currently being 
investigated. Even though advancements are being made 
in these fields, none of  these can provide detailed and ac-
curate enough information to replace the liver biopsy. For 
a more comprehensive summary of  recent non-invasive 
tests, the reader is referred to current reviews[31,32].
In summary an adequate liver biopsy, with appropriate 
clinical history, interpreted by a trained liver pathologist, 
is not only pivotal for an accurate and complete diagnosis 
(or exclusion) of  NAFLD (or NASH), but also is optimal 
for obtaining detailed information regarding disease pat-
tern, severity and fibrosis. It provides important infor-
mation with respect to subtypes, potential future risks, 
possible etiology, and natural history of  disease, and sets 
the ground work for future molecular studies and clinical 
trials, assisting clinical colleagues and patients with treat-
ments and follow-up.
HISTOLOGIC FEATURES, GRADING, AND 
STAGING OF NAFLD: ADULTS
In NAFLD, 5% or more macrovesicular steatosis is re-
quired for the diagnosis. This may occur with or without 
other findings, but without it, the diagnosis cannot be 
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population in liver, are an important component of  the 
innate immune system[81] and are implicated in the devel-
opment and the progression of  steatohepatitis[82,83] as well 
as in fibrosis[83].
Occasional polymorphonuclear leukocytes may also 
occur as a part of  lobular inflammation. When intense 
and encircling hepatocytes (i.e., satellitosis), one should 
consider alcoholic hepatitis (Figure 1H). The intensity 
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Figure 1  Histologic features, grading, and staging of nonalcoholic fatty liver disease. A: Mixed large and small droplet steatosis, single droplet, with nucleus 
pushed to one side, HE stain, 600 ×; B: Microvesicular steatosis, nuclei in the center with foamy cytoplasm, and megamitochondria HE stain, 600 ×; C: Ballooned 
hepatocytes with flocculent cytoplasm, HE stain, 600 ×; D: Loss of cytoplasmic expression of keratin 8/18 in ballooned hepatocytes, 600 ×; E: Mallory-Denk body, HE 
stain, 600 ×; F: Mallory-Denk body in blue-green color and dense perisinusoidal fibrosis, Trichrome stain, 600 ×; G: Portal lipogranuloma, HE stain, 400 ×; H: Mallory-
Denk bodies and satellitosis HE stain, 600 ×; I: Delicate perisinusoidal fibrosis, Trichrome stain, 600 ×; J: Bridging fibrosis, Trichrome stain, 200 ×.








and distribution of  the inflammation varies within the 
lobule. In some cases, the intense inflammation in zone 
3 may be confused with a portal area with the duct ob-
scured by inflammation. This may be particularly true in 
the cases when an artery branch is readily appreciated in 
zone 3[84].
Portal inflammation in NAFLD/NASH can be seen 
in 4 situations in increased amounts. In most cases, how-
ever, it is usually milder than lobular inflammation, and 
mononuclear cells are typically predominant[85]. Increased 
portal inflammation in active NASH has been associ-
ated with increased steatosis, ballooning and fibrosis in 
a series of  728 adult and 205 pediatric biopsies[86]. Ad-
ditionally, portal inflammation was noted to predominate 
along with portal fibrosis in a study of  100 pediatric 
NAFLD biopsies[87]. When portal inflammation is un-
usually prevalent, or when lymphoid aggregates occur in 
adult NAFLD or NASH, one should consider the possi-
bility of  a concurrent liver disease such as viral hepatitis, 
autoimmune liver disease, as examples[36,88]. Liver biopsy 
data has shown that pathologists are capable of  diag-
nosing NASH concurrently with another serologically 
positive liver disease, in particular, HCV, but the criteria 
may differ. This concept was shown by 3 separate stud-
ies; 2 retrospective reviews of  large biopsy series[36,38] 
and a prospective study[89]. One group emphasized the 
necessity of  stricter histologic criteria when evaluating 
NASH with other diseases by focusing on the charac-
teristic zone 3 perisinusoidal fibrosis of  the former that 
does not occur in the latter[36]. The fourth consideration 
is increased portal inflammation compared to lobular 
in adult patients following otherwise effective interven-
tion[29]. Finally, a different type of  portal inflammation, 
i.e., polymorphonuclear leukocytes accompanying peri-
portal ductular reaction may be indicative of  ALD with 
pancreatitis or other forms of  biliary obstruction.
Studies have demonstrated expansion of  the peri-
portal progenitor cell compartment in NASH. Hepatic 
progenitor cells (HPC) reside within the canal of  Her-
ing, along the limiting plate. They are rarely visualized by 
light microscopy unless activated. HPC are characterized 
by high N:C, round to spindled cytoplasm, ovoid nuclei 
and positivity for keratin 7 and 19; these characteristics 
are altered with progressive stages of  development to-
wards hepatocellular or biliary epithelium. In certain cir-
cumstances of  liver injury and repair, stem cell markers, 
Hedgehog pathway markers and others are also reported 
in activated HPC[90]. Roskams et al[91] demonstrated in-
creased number of  progenitor cells in patients with 
NASH and ALD; the study further showed correlation 
between numbers of  hepatic progenitor cells and fibrosis 
stage. In a multi-center study of  subjects before and after 
various forms of  treatment, the investigators demonstrat-
ed expansion of  progenitor cell component, correlation 
between ductular reaction, steatosis, amount of  portal in-
flammation, and NASH activity grade[19]. The group went 
on to demonstrate that the ductular reaction correlated 
with p21 positive replicative arrest in hepatocytes which 
was also associated with NASH activity and with insulin 
resistance. This area of  epithelial-mesenchymal commu-
nication is one of  ongoing interest in NASH.
Apoptotic hepatocytes are common both in NASH 
and ALD. Investigators have found that increased apop-
tosis is associated with disease severity[92,93], as well as 
fibrosis in NASH[92].
Isolated arteries observed in zone 3 correlated with 
advanced fibrosis in NASH[84]. Care must be taken to 
not confuse this region for a portal tract when there is 
marked inflammation.
Iron deposition, typically mild, can be noted as punc-
tate granules within reticuloendothelial lining cells and 
as granules or blush within hepatocytes. It has been re-
ported in 15%-55% of  cases[94]. Reticuloendothelial iron 
deposition was associated with steatosis, ballooning, por-
tal inflammation, and fibrosis in a study of  849 patient 
biopsies from the NASH CRN[95,96]. The relationships of  
iron deposition, hepcidin, iron regulatory genetics, ad-
vanced fibrosis and insulin resistance in fatty liver disease 
are complex and under intense investigation[96-99].
The typical pattern of  fibrosis in adult NASH is ini-
tially located in zone 3 in the perisinusoidal spaces in a 
pattern that is described as pericellular. When delicate, it 
is best appreciated with Masson trichrome or other col-
lagen stains (Figure 1I). As the disease progresses, the 
fibrosis becomes denser in zone 3 perisinusoidal spaces 
and, with further progression, portal and periportal fibro-
sis can be appreciated. At that point, ductular reaction is 
often present. In time, central-central, central-portal, or 
portal-portal bridging, architectural remodeling and final-
ly cirrhosis may occur (Figure 1J). In the advanced stages 
of  fibrosis and remodeled architecture, perisinusoidal 
fibrosis may no longer be present. Cartoon depiction of  
progression may be seen in texts[100].
GRADING AND STAGING THE LESIONS 
OF NAFLD/NASH
In 1999, a semi-quantitative grading and staging system 
to describe and unify the approach of  pathologists to the 
histopathologic lesions of  NASH and fibrosis along with 
architectural alterations, was proposed by Brunt et al[101]. 
The system was developed from evaluation of  51 liver 
biopsies of  NASH, and followed the broad method 
recently developed for chronic hepatitis of  separating 
activity (grade) from fibrosis (stage), with the recognition 
that NASH was not a portal-based process[102]. A semi-
quantitative activity grade was assigned by a combination 
of  parameters including steatosis, lobular and portal in-
flammation, and hepatocyte ballooning (Table 1). Fibro-
sis staging was based on fibrosis patterns of  adult NASH, 
and reflects the progression of  fibrosis as well as subse-
quent architectural remodeling. Figures 1I and J illustrate 
Stages 1 and 3. The details of  staging system can be seen 
in Table 2.
In 2002 the Brunt grading and staging was revised by 
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NASH CRN for use as a feature-based system in clinical 
trials. The system was published in 2005, and has come 
to be known as “NAFLD Activity Score (NAS)”[65]. The 
NASH CRN Scoring system includes the entire spectrum 
of  lesions that can be seen in the full range of  NAFLD 
and NASH, including pediatric liver disease (Table 3). 
The disease activity score represents the unweighted sum 
of  scores for steatosis, hepatocyte ballooning, and lobular 
inflammation. The fibrosis stage is an expansion of  the 
Brunt scoring, with additional subdivisions to stage 1 (1a-
mild perisinusoidal fibrosis, 1b-moderate perisinusoidal 
fibrosis, and 1c-portal fibrosis only, as occurs in pediatric 
NAFLD).
Alkhouri et al[103] recently published a calculated pe-
diatric NAFLD histological score (PNHS), using the 
histologic parameters in NAS. The PNHS consists of  
weighted sum of  steatosis, hepatocyte ballooning, lobular 
inflammation and portal inflammation. The “borderline 
NASH” category has been eliminated from the pediatric 
scoring system and high scores are associated with a di-
agnosis of  NASH in this patient group[103]. The reader is 
referred to the reference for the calculation.
Most recently, an algorithmic approach to scoring 
has been proposed by Bedossa et al[104] based on over 
600 bariatric patient liver biopsies. The SAF (steatosis, 
activity, fibrosis) system is a sum of  scores of  steatosis, 
activity (hepatocyte ballooning + lobular inflammation) 
and fibrosis. Many details are modeled on the criteria by 
NASH CRN[65]. The SAF system differs from NAS in 
three major areas: it includes fibrosis into the final score, 
it excludes steatosis from the activity score and one is 
able to derive a diagnosis of  NASH from a numeric value 
of  SAF. It is noteworthy that the proponents of  this sys-
tem do not take patterns of  any of  the lesions or any as-
sessments of  portal inflammation into account. Further 
validation of  this method in non-morbidly obese subjects 
is awaited.
In summary, grading and staging systems are use-
ful tools in terms of  providing a standard in pathology 
reporting, monitoring response to treatment and/or 
progression of  disease both in patient care and clinical 
trials. However, the diagnosis of  NAFLD depends on 
interpreting a variety of  histologic findings and patterns 
and, cannot be replaced or reflected with a single number 
or score.
PEDIATRIC NAFLD
One of  the most consistent observations of  pediatric 
NAFLD that differed from adults was the difference in 
distribution of  the fat, and the preferential accentuation 
of  portal inflammation and fibrosis (Figure 2A, B). Ste-
atosis is commonly either panacinar or distinctly periportal 
(zone 1)[87,105-107]. From a study that resulted in a hierarchi-
cal analysis of  100 pediatric biopsies, Schwimmer pro-
posed two dominant subtypes of  pediatric NAFLD: Type 
1, the least common, but seen in Caucasian girls and with 
the similar zone 3 accentuation as with adult NAFLD, and 
Type 2, the most common, seen more often in boys and 
characterized by either panacinar or periportal steatosis, 
portal-predominant inflammation and portal-based fibro-
sis, and most commonly encountered in Asian, Hispanic 
or Native American ethnic groups. The remainder of  the 
biopsies were “overlap” or steatosis[87]. Carter-Kent et al[108] 
studied a large multi-ethnic overweight biopsy population 
from several North American centers and found less abil-
ity to clearly separate the biopsies into discrete patterns 
with an overlap of  the two main patterns in 82% of  cases. 
Nobili et al[109] also noted more overlap (52.4%) than either 
Type 1 or 2 in a series of  84 Italian overweight subjects. 
The NASH CRN refers to zone 1 (periportal) pattern as 
“borderline, zone 1”, and zone 3 pattern as “borderline, 
zone 3”, and has found similar ethnic correlations to Pat-
ton et al[110]. Both patterns have been seen in blinded bi-
opsy reviews by the Central Pathology Committee in adult 
biopsies, albeit in small numbers. Interestingly, to date, 
there is yet to be a definitive agreement amongst expert 
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Table 1  Brunt grading system
Grade Steatosis Ballooning Inflammation
Mild (1) 1-2 (< 66%) Minimal L: 1-2 P: 0-1
Moderate (2) 2-3 Present-zone 3 L: 2 P: 1-2
Severe (3) 2-3 Marked-zone 3 L: 3 P: 1-2
Reproduced with permission[101]. Steatosis: grade 1: < 33%; grade 2: > 
33%-66%; grade 3: > 66%. Lobular inflammation: grade 1: < 2 foci per 200 
× field; grade 2: 2-4 foci per 200 × field; grade 3: > 4 foci per 200 × field. 
Portal inflammation: grade 0: None; grade 1: Mild; grade 2: Moderate; 
grade 3: Severe. Ballooning: grade 1: Rare; grade 2: Prominent ballooning. 
L: Lobular/acinar inflammation; P: Portal inflammation.
Table 2  Brunt staging system
Stage Zone 3 PSF, focal or 
extensive
Portal, periportal Bridging Cirrhosis
1 + 0 0 0
2 + + 0 0
3 +/- +/- + 0
4 +/- +/- +/- +
Reproduced with permission[101]. PSF: Perisinusoidal fibrosis.
Table 3  Nonalcoholic steatohepatitis clinical research net-
work nonalcoholic fatty liver disease scoring system
Steatosis grade Lobular inflammation Liver cell ballooning
0: < 5% 0: No foci 0: None
1: 5%-33% 1: < 2 foci per 200 × field 1: Few ballooned hepatocytes
2: 34%-66% 2: 2-4 foci per 200 × field 2: Many ballooned 
hepatocytes
3: > 66% 3: > 4 foci per 200 × field
Reproduced with permission[65]. Nonalcoholic fatty liver disease activity 
score (NAS): Steatosis + inflammation + ballooning. Fibrosis, 0: None; 1: 
Perisinusoidal or periportal;  1A: Mild, zone 3 perisinusoidal;  1B: Moder-
ate, zone 3 perisinusoidal; 1C: Portal, periportal; 2: Perisinusoidal and 
portal/periportal; 3: Bridging fibrosis; 4: Cirrhosis.
Nalbantoglu I et al . NAFLD and liver biopsy
pathologists in the field for pediatric NASH histology, un-
less there are the very same characteristics found in adult 
NASH, as described above. There is also no knowledge 
about when or how a transition may occur from pedi-
atric patterns to adult patterns of  disease, but an initial 
retrospective cross-sectional review of  186 NASH CRN 
biopsies has shown that comparing biopsies from chil-
dren during prepuberty, puberty and post puberty, there 
is less steatosis and portal inflammation, but increased 
steatohepatitis and Mallory-Denk bodies with the change 
in age[111]. These findings are strongly suggestive that with 
the changes of  aging and associated hormonal alterations 
and shifts of  insulin sensitivity, the liver is more suscep-
tible to the injury of  increased free fatty acids and lipotox-
icity. Natural history studies with prospective biopsies are 
needed in this growing population.
DIFFERENTIATION FROM ALCOHOLIC 
LIVER DISEASE
Some histologic features of  NASH and ALD such as 
steatosis, hepatocyte injury (including ballooning, ne-
crosis and apoptosis, MDBs), and lobular inflammation 
are shared[112]. However, in ALD lobular inflammation 
may show clusters of  PMNs; when present, the lesion is 
known as “satellitosis”. The lesion is a clue to the pres-
ence of  MDB, often in apoptotic hepatocytes (Figure 
1H). Steatosis is not a diagnostic requirement for ALD. 
An unusual form of  ALD is nearly all microvesicular ste-
atosis and is referred as “alcoholic foamy degeneration”; 
there is no equivalent described in NASH. Canalicular 
cholestasis and features of  pancreatitis or biliary obstruc-
tion (ductular reaction accompanied by marked acute in-
flammation and edema) can occur in ALD; these lesions 
have not been described in NASH. Thickening and peri-
venular fibrosis of  terminal hepatic venules and, veno-
occlusive lesions are described in ALD[113]. Sclerosing 
hyaline necrosis (obliteration of  terminal hepatic venules, 
hepatocyte necrosis and MDBs) is exclusive to severe al-
coholic hepatitis[112,113].
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